When Desperation Becomes a Business Model
In the depths of America's opioid crisis — a catastrophe that claimed more than 80,000 lives to overdose in 2023 alone, according to the CDC — a parallel industry has quietly flourished: the private addiction treatment market. It is an industry that generates an estimated $42 billion annually, according to IBISWorld, and one that operates in a regulatory environment so fractured and permissive that predatory actors have been allowed to treat suffering human beings as revenue streams. Federal and state oversight has failed the people most in need, while well-connected facility operators pocket insurance reimbursements for care that ranges from inadequate to actively harmful.
At the center of this crisis-within-a-crisis is a practice known as patient brokering — a scheme in which recruiters, sometimes called "body brokers," are paid kickbacks to funnel people struggling with addiction into particular treatment facilities, regardless of whether those facilities are equipped to help them. Florida, which became the epicenter of this racket in the 2010s, saw so many abuses that the state legislature passed the Patient Brokering Act in 2017. But enforcement has been uneven, and the underlying economics that make brokering profitable — generous out-of-network insurance reimbursements for substance use treatment, mandated by the Affordable Care Act's parity provisions — remain largely intact across the country.
The Luxury Rehab Illusion
At the premium end of the market, so-called luxury rehabilitation facilities charge upward of $30,000 to $100,000 per month for treatment that frequently bears little resemblance to what the clinical evidence actually supports. These facilities offer equine therapy, ocean-view accommodations, and gourmet meals — amenities that serve as marketing tools rather than therapeutic interventions. Meanwhile, the gold-standard treatment for opioid use disorder — medication-assisted treatment, or MAT, using buprenorphine or methadone — is frequently absent, minimized, or actively discouraged at these centers, often because of ideological opposition rooted in the abstinence-only model that has dominated American addiction treatment for decades despite being repeatedly contradicted by peer-reviewed research.
The Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute on Drug Abuse have both affirmed that MAT reduces mortality, decreases illicit drug use, and improves long-term recovery outcomes. Yet a 2020 study published in the Journal of Substance Abuse Treatment found that fewer than half of private residential treatment facilities offered any FDA-approved medication for opioid use disorder. Patients are instead cycled through 28-day residential programs — a duration determined not by clinical science but by the history of insurance reimbursement structures — then discharged into communities with little follow-up support, only to relapse and re-enter the system. In the industry, this is sometimes called the "revolving door," and for facility operators, it is a feature rather than a bug.
Who Gets Left Behind
The cruelest dimension of this market failure is its geography of exclusion. Working-class and low-income Americans — the demographic most devastated by the opioid crisis, particularly in rural Appalachia, the Rust Belt, and tribal communities — are systematically priced out of even the most rudimentary evidence-based care. Medicaid, which covers a disproportionate share of people with substance use disorders, reimburses addiction treatment at rates so low that many quality providers refuse to accept it. The result is a two-tier system: if you have premium private insurance or personal wealth, you can access residential treatment of variable quality; if you are poor, you may wait months for a bed in a publicly funded program — if one exists in your county at all.
In rural counties, the shortage is acute. The Health Resources and Services Administration has designated hundreds of counties as Mental Health Professional Shortage Areas, and the overlap with communities hit hardest by opioids is not coincidental. Methadone, despite being one of the most effective treatments for opioid use disorder, can only be dispensed through federally certified opioid treatment programs — clinics that are heavily concentrated in urban areas and subject to zoning restrictions that communities frequently exploit to keep them out. A person in eastern Kentucky or rural West Virginia may have to drive two hours each way, every day, to receive a medication that could save their life.
The Strongest Case for the Other Side
Defenders of the private treatment market argue that it drives innovation, expands capacity beyond what public systems could sustain, and gives patients choice. There is something to the capacity argument: publicly funded treatment slots are genuinely insufficient, and eliminating private providers without a credible replacement would leave a dangerous void. Some private operators run ethical, evidence-based programs and fill genuine gaps in the care continuum.
But the strongest version of the market argument collapses when confronted with the structural incentives at play. In a market where the consumer is in acute psychological crisis, where information asymmetry is extreme, where the consequences of a bad choice can be fatal, and where insurance reimbursement rather than clinical outcomes drives facility decisions, the conditions for a functioning market simply do not exist. The analogy is not a consumer choosing between car dealerships — it is closer to a drowning person choosing between lifeboats of unknown seaworthiness while someone charges by the hour to watch.
What a Real Recovery Infrastructure Looks Like
A genuinely public-health-centered approach to addiction would look nothing like the current system. It would expand MAT access dramatically, including through mobile units and primary care integration, removing the bureaucratic barriers that make methadone access a daily logistical ordeal. It would fund community-based recovery support services — peer counselors, stable housing, job placement — that address the social determinants that drive relapse. It would establish federal minimum standards for addiction treatment facilities and create a meaningful accreditation and enforcement regime with real teeth. And it would treat the patient brokering industry for what it is: organized fraud, prosecutable under federal wire fraud and anti-kickback statutes, deserving of consistent and aggressive enforcement.
Some of these reforms were embedded in the SUPPORT for Patients and Communities Act, passed with bipartisan support in 2018, but implementation has been halting and funding inadequate. The Biden administration expanded buprenorphine prescribing access by eliminating the X-waiver requirement in 2023 — a genuine, evidence-based policy win. But deregulating prescribing access means little if the underlying healthcare infrastructure to support patients in recovery does not exist in the communities that need it most.
The Political Stakes
The opioid crisis has never been neatly partisan — it has devastated red states and blue states alike, rural counties and mid-sized cities, white working-class communities and communities of color. That political cross-cutting reality is precisely why it represents an opportunity for genuine policy movement, if the political will can be assembled. But that will not happen while a well-resourced treatment industry lobbies to preserve reimbursement structures that reward volume over outcomes, and while the abstinence-only ideology that has historically dominated Republican-aligned faith communities continues to obstruct evidence-based care.
The lives lost to this failure are not abstractions. They are parents, children, neighbors, and colleagues — people whose suffering was real and whose deaths were, in many cases, preventable. A society that is serious about the value of human life does not outsource addiction treatment to the lowest ethical bidder.
America cannot afford to keep treating recovery as a commodity — the cost, measured in lives, is already catastrophic.
